IRCT20191228045924N2 IRCT 2021-11-22 Mashhad University of Medical Sciences Investigation of Methylene Blue for treatment of COVID-19 outpatients referred to pulmonary clinic. Application of Methylene Blue Along with Complementary Materials for Treatment of COVID-19 Outpatients with Less Than 8 Days from First Day of Clinical Symptoms 2021-11-25 anticipated 240 Complete https://irct.ir/trial/60065 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization method: simple randomization, randomization unit: individual, randomization tool: by using the website of randomization: https://www.random.org/lists/ Simple randomization is done by random numbers generated by the randomization site, according to the list produced, individuals will be randomly assigned to the intervention (methylene blue) or control groups, Blinding description: In this single blind, the evaluator, who is a health care professional (nurse) and is responsible for collecting data (symptoms and hospitalization and mortality) from patients after using the drug, is not aware that each patient belongs to control group or intervention group. 4 COVID-19. Intervention 1: Intervention group: In addition to the standard treatment, Covid-19 outpatients are received orally methylene blue along with complementary materials two times per day in interval time 12 hours. The drug is used for 7 days until 14 days. Drug is prepared by Omid Rajabi pharmaceutical company. Methylene Blue (1 mg/Kg), Vitamin C, Glucose or sugar, Vitamine B1, B2, B3, Calcium Phosphate, Citrate Potassium, Carbonate Sodium, Glycine Amino Acid, Ginger, Lecithin, Ascorbyl Palmitate, Magnesium Stearate will be prepared as powder (in one sacchet) and it will used orally after dissolving in water. Intervention 2: Control group: Patients will received just the standard treatment. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no further information.